EX-99.1 2 ex99-1.htm EX-99.1

 

Exhibit 99.1

 

 

InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow

 

The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and sustained profitability with its eleventh consecutive half of positive Adjusted EBITDA amidst ongoing recovery in Israel

 

InterCure is encouraged by recent regulatory momentum in the U.S. and believes that it is well positioned to capitalize on evolving U.S. cannabis rescheduling, especially following its recent signing of an agreement to acquire ISHI

 

NEW YORK and HERZLIYA, Israel, October 8, 2025 – InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (“InterCure” or the “Company”), today announced its financial and operating results for the first half of 2025.

 

Alexander Rabinovitch, CEO of InterCure, stated: “In the first half of 2025, InterCure delivered revenues of NIS 130 million, achieving positive Adjusted EBITDA for the eleventh consecutive half year period and generating NIS 12 million in positive operating cash flow. This performance underscores the strength of our vertically integrated business model and our ability to navigate a challenging environment, including the impact of the October 7 attack and the ongoing war in Gaza. We continue to work closely with Israeli authorities to secure full compensation for damages to our southern facility.

 

Looking ahead, we are confident in our ability to continue our recovery growth trajectory, expanding our international footprint, and strengthen our leadership in the pharmaceutical cannabis industry, particularly with the strategic acquisition of ISHI, which positions us to capitalize on evolving opportunities in the global cannabis market. At the same time, we are closely monitoring regulatory developments in the U.S. regarding potential rescheduling of cannabis.”

 

First Half 2025 Financial Highlights

 

(All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted)

 

●Revenue of NIS 130 million, an increase of 15% compared to the second half of 2024, and an increase of 3% compared to NIS 126 million in the first half of 2024.

 

●Net loss of NIS 1.8 million, compared to near break-even in the first half of 2024.

 

●Adjusted EBITDA of NIS 12.6 million, representing 10% of revenue, marking the Company’s eleventh consecutive half of positive Adjusted EBITDA.1

 

●Positive cash flow from operations of NIS 12 million, compared to negative cash flow of NIS 43 million in the same period last year.

 

●Cash on hand of NIS 54 million as of June 30, 2025, compared to NIS 21 million as of June 30, 2024.2

 

●Shareholders’ equity of NIS 432 million as of June 30, 2025.

 

 

 

1 Adjusted EBITDA means net income (loss) before interest, taxes, depreciation and amortization adjusted for changes in the fair value of inventory, share-based payment expense, impairment losses (and gains) on financial assets, and other expenses (or income). Other income, net includes war-related damage compensation from the tax authorities, changes to allowance for credit risk and impairment of inventory.

2 Including restricted cash and deposits.

 

 
 

 

Operational and Strategic Highlights

 

●As the recovery process progresses, the Company resumed production, importation and sales from the Nir Oz facility, delivering first batches since the October 7, 2023 attack and the ongoing war in Gaza.

 

●Launched more than 40 new SKUs during the first half of 2025, marking the first major product launches since October 2023.

 

●Received NIS 81 million in compensation advances from Israeli authorities for war-related damages, as part of a total submitted damages3 of NIS 251 million.

 

●Continued expansion of Canndoc’s medical cannabis pharmacy chain and growing global demand for InterCure’s pharmaceutical-grade cannabis products.

 

●In September 2025, the Company entered into a share purchase agreement to acquire Botanico Ltd. (ISHI), a strategic acquisition expected to strengthen InterCure’s access to premium U.S. genetics, advanced cultivation technologies, and international market opportunities.

 

●The Company is closely monitoring regulatory developments in the U.S. regarding potential rescheduling of cannabis and believes that it is well positioned to capitalize on evolving U.S. cannabis landscape, especially following its recent signing of an agreement to acquire ISHI.

 

●Under the purchase agreement with respect to ISHI, the Company obtained exclusive supply of premium products under The Flowery™ and leading American brands, which are expected to contribute tens of millions of shekels to the Company’s revenues.

 

About InterCure (dba Canndoc)

 

InterCure (dba Canndoc) (NASDAQ: INCR) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated “seed-to-sale” model to lead the fastest growing cannabis global market outside of North America.

 

For more information, visit: https://www.intercure.co

 

 

 

3 The claim is not final and remains subject to adjustment. The total amount claimed may be increased as further information becomes available.

 

 
 

 

Non-IFRS Measures

 

This press release makes reference to certain non-IFRS financial measures. Adjusted EBITDA, as defined by InterCure, means earnings before interest, income taxes, depreciation, and amortization, adjusted for changes in the fair value of inventory, share-based payment expense, impairment losses (and gains) on financial assets, and other income, net which included war-related damage compensation from the tax authorities, changes to allowance for credit risk, and impairment of inventory. This measure is not a recognized measure under IFRS, does not have a standardized meaning prescribed by IFRS and is therefore unlikely to be comparable to similar measures presented by other companies. InterCure’s method of calculating this measure may differ from methods used by other entities and accordingly, this measure may not be comparable to similarly titled measures used by other entities or in other jurisdictions. InterCure uses this measure because it believes it provides useful information to both management and investors with respect to the operating and financial performance of the Company.

 

Forward-Looking Statements

 

This press release contains forward-looking statements. Forward-looking statements may include, but are not limited to, the Company’s expected growth, including in Adjusted EBITDA, success of its global expansion plans, its expansion strategy to major markets worldwide, expected receipt of additional compensation from the Israeli government, and the expected completion of the acquisition of ISHI, as well as statements, other than historical facts, that address activities, events or developments that InterCure intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause InterCure’s actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company’s success in executing its global expansion plans (including the pending acquisition of Botanico Ltd. (ISHI)), its continued growth, expected operations and financial results, business strategy, competitive strengths, goals and expansion into major markets worldwide, the impact of the war in Israel and the war in Ukraine, and the conditions of the markets generally. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond InterCure’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to: changes in general economic, business and political conditions, changes in applicable laws, the U.S. regulatory landscape and enforcement related to cannabis, changes in public opinion and perception of the cannabis industry, and reliance on the expertise and judgment of our senior management. More detailed information about the risks and uncertainties affecting us is contained under the heading “Risk Factors” included in the Company’s most recent Annual Report on Form 20-F, as well as in the Company’s Form 6-K containing the unaudited condensed consolidated financial statements for the six months ended June 30, 2025, and in other filings that we have made and may make with the Securities and Exchange Commission in the future.

 

Company Contact:

InterCure Ltd.

Amos Cohen, Chief Financial Officer

amos@intercure.co

 

Investor Relations Contact:

Arx Investor Relations

North American & Israeli Equities Desks

intercure@arxhq.com

 

 

 

 

Condensed Consolidated Interim Statements of Financial Position (Unaudited)

As of June 30, 2025

 

   As of June 30 
   NIS in thousands 
   2025   2024 
ASSETS          
           
CURRENT ASSETS:          
Cash and cash equivalents   51,334    19,899 
Restricted cash and deposits   2,436    948 
Trade receivables, net   46,931    61,672 
Other receivables   119,604    158,045 
Inventory   148,174    126,466 
Biological assets   5,269    3,388 
Financial assets measured at fair value through profit or loss   250    399 
Total current assets   373,998    370,817 
           
NON-CURRENT ASSETS:          
Other receivables   5,824    439 
Property, plant and equipment and right-of-use asset   105,046    98,611 
Goodwill   224,778    223,609 
Deferred tax assets   39,970    27,042 
Financial assets measured at fair value through profit or loss   2,147    1,922 
Investment in associate and loan    -    18,447 
Total non-current assets   377,765    370,070 
           
TOTAL ASSETS   751,763    740,887 
           
LIABILITIES AND EQUITY          
           
CURRENT LIABILITIES:          
Short term loan and current maturities   62,767    81,755 
Trade payables   90,785    83,071 
Other payables   44,454    39,965 
Contingent consideration   3,966    4,082 
Total current liabilities   201,972    208,873 
           
LONG-TERM LIABILITIES:          
Long term loans   94,917    51,317 
Liabilities in respect of employee benefits   973    841 
Lease liability   21,657    17,741 
Total long-term liabilities   117,547    69,899 
           
EQUITY:          
Share capital, premium and other reserves   675,393    649,013 
Capital reserve for transactions with controlling shareholder   2,388    2,388 
Receipts on account of shares   19,591    - 
Capital reserve for transactions with non-controlling interests   13,561    13,561 
Accumulated losses   (279,786)   (204,518)
Equity attributable to owners of the Company   431,147    460,444 
           
Non-controlling interests   1,097    1,671 
TOTAL EQUITY   432,244    462,115 
           
TOTAL LIABILITIES AND EQUITY   751,763    740,887 

 

 

 

 

Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income (Unaudited)

 

  

For the 6-months

ended on June 30

  

Year endd

December 31

 
   NIS in thousands 
   2025   2024   2024 
             
Revenue   130,011    125,733    238,845 
Cost of revenue before fair value adjustments   91,449    85,291    203,252 
                
Gross income before impact of changes in fair value   38,562    40,442    35,593 
                
Unrealized changes to fair value adjustments of biological assets   1,661    1,218    6,458 
Loss from fair value changes realized in the current year   2,005    1,029    11,818 
                
Gross Profit   38,218    40,631    30,233 
                
Research and development expenses   191    219    414 
General and administrative expenses   14,302    18,374    53,669 
Sales and marketing expenses   26,115    27,454    54,225 
Other expenses, net   (9,074)   (16,414)   (12,807)
Changes in the fair value of financial assets through profit or loss, net.   83    (201)   (341)
Share based payments   885    686    2,281 
                
Operating Profit   5,716    10,513    (67,208)
                
                
Financing income   2,356    1,031    2,747 
Financing expenses   10,369    10,070    22,862 
                
Financing expenses (income), net   8,013    9,039    20,115 
                
Profit before tax on income   (2,297)   1,474    (87,323)
                
Tax (expense) benefit   485    (1,480)   14,530 
Total comprehensive Profit (loss)   (1,812)   (6)   (72,793)
                
Profit (loss) attributable to:               
Owners of the Company   (1,704)   1,433    (67,795)
Non-controlling interests   (108)   (1,439)   (4,998)
Total   (1,812)   (6)   (72,793)
                
Earnings per share               
Basic earnings (loss)   (0.03)   0.03    (1.48)
Diluted earnings (loss)   (0.03)   0.03    (1.48)

 

Non-IFRS Financial Measures

 

Total comprehensive Profit (loss)   (1,812)   (6)   (72,793)
Interest / Financing expense (income) net   8,013    9,039    20,115 
Tax expenses (benefit)   (485)   1,480    (14,530)
Depreciation and amortization   8,451    6,337    15,371 
EBITDA   14,167    16,850    (51,837)
Share-based payment expenses   885    686    2,281 
Other income, net   (9,074)   (16,414)   (12,807)
War-related damage compensation from the tax authorities   9,019    16,830    42,468 
Changes to allowance for credit risk   (2,844)        16,878 
Impairment of inventory    -     -    15,960 
Changes in the fair value of financial assets through profit or loss, net   83    (201)   (341)
Fair value adjustment to inventory   344    (189)   5,360 
Adjusted EBITDA   12,580    17,562    17,962 

 

For More Financial Information:

 

For a comprehensive understanding of the Company’s financial reports and related management’s discussion and analysis for applicable periods, please review the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2024, and the Company’s Form 6-K containing the unaudited condensed consolidated financial statements for the six months ended June 30, 2025, both available on the Company’s EDGAR profile at https://www.sec.gov/edgar